# Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

> **NCT03160885** · PHASE3 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 794 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tralokinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03160885
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2018-09-04
- **Final completion:** 2019-08-14
- **Target enrollment:** 794 (ACTUAL)
- **Last updated:** 2025-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03160885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03160885, "Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03160885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*